PYPD: PolyPid Quarterly EPS earnings growth

Public company logo of PolyPid (PYPD)

PolyPid Ltd. (PYPD) risks facing regulatory rejection and a funding shortage amid intensifying competition. Meanwhile, surgeons value PolyPid Ltd. for its innovative extended-release antibiotic delivery systems. Production is automated via PLEX conveyors, eliminating manual labor. The quarterly EPS growth history helps determine the asset's fundamental floor, with the latest mark standing at 54.90.

PolyPid Ltd (PYPD) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/11/2026

Summary analytical data breakdowns for PolyPid Ltd. (PYPD)

- share price and expert price forecast:
Stock Price polypid.com|PYPD - Forecast Levels Chart
- market capitalization information:
Market Capitalization PolyPid Limited|PYPD - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share PolyPid|PYPD - Company Net Assets|Market Cap to Net Assets Ratio polypid.com|PYPD - Aggregate Business Assets
- company liabilities and liquidity data:
Total Debt to Capital PolyPid Ltd.|PYPD - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity polypid.com|PYPD - Company Cumulative Debt|Debt to Book Capitalization Ratio PolyPid Limited|PYPD - Company Long-Term Indebtedness|Company Short-Term Debt PolyPid|Quick Liquidity polypid.com
- earnings and valuation multiples indicators:
PYPD - Profit After Tax|Expected Profit PolyPid Ltd.|PYPD - Market Cap to Earnings|Future Price to Earnings polypid.com|PYPD - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio PolyPid Limited|PYPD - Profit before interest, taxes and amortization|Earnings per share for the last twelve months PolyPid|PYPD - Earnings per one share for the last 12 months|Quarterly EPS earnings growth polypid.com|PYPD - Expected net earnings per share growth this year|Earnings growth forecast for next year PolyPid Ltd.
Comprehensive company analysis:PolyPid Ltd.
Flagship merchandise of polypid.com

PolyPid Ltd. is characterized by a critical dependence on FDA approval for the D-PLEX drug and a high risk of capital burn. The current value of 54.90 reflects the dynamics of net earnings per share, measuring the business's ability to generate real income amid clinical trials, which allows for an assessment of the company's resilience to shocks through the quarterly EPS growth trend and helps avoid overpaying for the asset.

Key competitors

SMMT: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months MRNA (Moderna Inc)|PCVX (Vaxcyte Corp) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tarsus Corp TARS|Quarterly EPS earnings growth CRMD|Year-over-year net earnings per share growth for the last 12 months serestherapeutics.com MCRB|Spero Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months SCYX (SCYNEXIS Inc)|AN2 Bio - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months YS Biopharma Co., Ltd. LSB|iterumtx.com (ITRM) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months BiomX (PHGE)|Year-over-year earnings per share growth for the last twelve months Soligenix Inc|Year-over-year earnings per share growth for the last 12 months SXTP (60 Degrees Pharma)|Year-over-year earnings per share growth for the last twelve months Oragenics, Inc. (OGEN)|Year-over-year net earnings per share change for the last twelve months OpGen Corporation